CLINICAL TRIALS AND OBSERVATIONS Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
نویسندگان
چکیده
1Institute of Hematology L. & A. Seràgnoli, University of Bologna, Bologna; 2Department of Hematology, University La Sapienza Rome, Rome; 3Department of Internal Medicine, S. Luigi Gonzaga Hospital Orbassano, Torino; 4Department of Hematology, University of Catania, Catania; 5Department of Hematology, University of Bari, Bari; 6Division of Hematology, Mazzoni Hospital, Ascoli Piceno; 7Hematology Unit, Giannettasio Hospital, Rossano Calabro; and 8Centro Indagini Genetiche e Molecolari, Federico II University, Napoli, Italy
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase
In chronic myelogenous leukemia (CML) imatinib mesylate has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent alone high rates of cytogenetic responses were recorded. However, several mechanisms of resistance have been described. In vitro studies examining the effects of imatinib mesylate plus cytarabine have shown synergistic...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-
Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronicphase CML after failure on interferonwere treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 mon...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within 1 month of diagnosis since 1965 were reviewed: 1148 chronic phase (CP), 175 accelerated phase (AP), and 246 blastic phase (BP). The median survival was 8.9 years in CP, 4.8 years in AP, and 6 months in BP. In CP, the 8-year survival was < 15% before 1983, 42%65% from 1983-2000, and 87% since 2001. Su...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase
The relative merits of allogeneic hematopoietic stem cell transplantation (alloHSCT) and imatinib for chronic myelogenous leukemia in the accelerated phase (AP-CML) have not previously been evaluated. This cohort study was designed to compare the outcomes of imatinib (n 87) versus allo-HSCT (n 45) for AP-CML. A multivariate analysis of the total population revealed that a CML duration > 12 mont...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
• This analysis demonstrates the universality of the early response in CML, regardless of the treatment modality used. • Factors correlating with poor cytogenetic responses at 3-mo assessment in a multivariate analysis across all 4 TKIs. Early responses to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)-chronic phase (CP) are associated with improved outcome. We analyzed the...
متن کامل